Ironwood Pharmaceuticals to Present at 27th Annual Credit Suisse Healthcare Conference
November 08 2018 - 4:05PM
Business Wire
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a
corporate update at the 27th Annual Credit Suisse Healthcare
Conference on Wednesday, November 14th, 2018 at 2:15 p.m. Mountain
Time (4:15 p.m. Eastern Time) at the Phoenician in Scottsdale,
Arizona.
A live webcast of Ironwood’s presentations will be accessible
through the Investors section of the company’s website at
www.ironwoodpharma.com. To access the webcasts, please log on to
the Ironwood website approximately 15 minutes prior to the start
time to ensure adequate time for any software downloads that may be
required. A replay of the webcasts will be available on Ironwood’s
website for 14 days following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a commercial
biotechnology company focused on creating medicines that make a
difference for patients, building value for our fellow
shareholders, and empowering our passionate team. We discovered,
developed and are commercializing linaclotide, the U.S. branded
prescription market leader for adults with irritable bowel syndrome
with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Our pipeline priorities for linaclotide include a Phase IIIb trial
evaluating its efficacy and safety on multiple abdominal symptoms,
including abdominal bloating, pain, and discomfort in adult
patients with IBS-C, as well as research into a formulation of
linaclotide designed to relieve pain across all IBS subtypes.
We are also advancing a pipeline of innovative product
candidates in areas of significant unmet need, including persistent
gastroesophageal reflux disease, diabetic nephropathy, heart
failure with preserved ejection fraction and sickle cell disease.
Ironwood was founded in 1998 and is headquartered in Cambridge,
Mass. For more information, please visit www.ironwoodpharma.com or
www.twitter.com/ironwoodpharma; information that may be important
to investors will be routinely posted in both these locations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181108005935/en/
Ironwood Pharmaceuticals, Inc.Meredith Kaya, 617-374-5082Vice
President, Investor Relations and Corporate
Communicationsmkaya@ironwoodpharma.com
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Apr 2023 to Apr 2024